Nurix Therapeutics, Inc.

Gilead Sciences' acquisition of Leo Pharma’s signal transducer and activator of transcription 6 (STAT6) program is not just a major boost for the Danish group’s finances but also a nod to the growing

NX-5948, Nurix Therapeutics’ treatment for relapsed or refractory chronic lymphocytic leukemia, and Ga68-PentixaFor, Pentixapharm’s radiodiagnostic for primary aldosteronism, are the latest investigat

The pharmaceutical, biotech and other allied industries came together in London on 4 December to celebrate another year of exceptional achievement at the 20th Annual Scrip Awards at the Raffles hotel

Nurix Therapeutics has presented updated Phase I data for NX-5948, an oral degrader of Bruton’s tyrosine kinase (BTK), showing strong response rates in patients who have relapsed or refractory B-cell